Tech at Polsky
Inventor(s):
This technology generates antigen specific immune tolerance for autoimmune or transplantation therapy via induction of tolerogenic dendritic cells (tolDC, PD-L1+, CD80- CD11c+)) which facilitate the differentiation of antigen specific Tregs.
The invention is a liposome loaded with immunosuppressive drugs, toll-like-receptor (TLR) agonists, and any antigen of interest. This unique co-formulation of activating and inhibitory signals generates a potent toIDC phenotype in vivo.
Reliable generation of antigen specific Tregs with minimal non-specific immune suppression
Long-lived immune tolerance
Easy manufacturing and storage
February 7, 2022
Proof of concept
Patent Pending
Licensing,Co-development
Aaron Esser-Kahn
Published 2/7/2022
Reference ID 22-T-003
Have Questions?
Contact Michael Hinton, Senior Manager, Technology Marketing, who can provide more detail about this technology, discuss the licensing process, and connect you with the inventor.
This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.